有毛細胞白血病治療薬の世界市場:化学療法、標的療法

Technavioが発行した調査報告書(IRTNTR31795)
◆英語タイトル:Global Hairy Cell Leukemia Therapeutics Market 2019-2023
◆商品コード:IRTNTR31795
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月31日
◆ページ数:129
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア太平洋、ヨーロッパ、北米、その他
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社の本調査レポートでは、有毛細胞白血病治療薬の世界市場について調べ、有毛細胞白血病治療薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、有毛細胞白血病治療薬の市場規模をセグメンテーション別(製品別(化学療法、標的療法)、)と地域別(アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は有毛細胞白血病治療薬の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・有毛細胞白血病治療薬の市場状況
・有毛細胞白血病治療薬の市場規模
・有毛細胞白血病治療薬の市場予測
・有毛細胞白血病治療薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(化学療法、標的療法)
・有毛細胞白血病治療薬の顧客状況
・主要地域別市場規模:アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Hairy Cell Leukemia Therapeutics Market: About this market

Hairy cell leukemia is a rare, slow-growing subtype of leukemia, which accounts for about 2% of the total cases of leukemia. Technavio’s hairy cell leukemia therapeutics analysis considers sales from both chemotherapies and targeted therapy. Our analysis also considers the sales of hairy cell leukemia therapeutics in North America, Europe, Asia, and the rest of the world (ROW). In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of leukemia, including hairy cell leukemia, will play a significant role in the chemotherapy segment to maintain its market position. Also, our global hairy cell leukemia therapeutics market report looks at factors such as increased exposure to hazardous substances leading to hairy cell leukemia, growing geriatric population, strategic alliances. However, limited patient pool, adverse effects of chemotherapy drugs, difficulty in diagnosis may hamper the growth of the hairy cell leukemia therapeutics industry over the forecast period.

Global Hairy Cell Leukemia Therapeutics Market: Overview

Increasing exposure to hazardous substances leading to hairy cell leukemia

Exposure to such hazardous substances can happen due to various types of occupations such as farming, working in manufacturing plants dealing with hazardous chemicals and fumes, and working in coal mines, cement- and gravel-producing plants. Exposure to chemical fertilizers and pesticides is continuously increasing as the lack of nutrients in the soil has increased the use of fertilizers to provide required nutrients and to improve agriculture yields. Thus, to meet the food demand of the ever-increasing population, chemical fertilizers are increasingly used, which is expected to increase the prevalence of hairy cell leukemia which, in turn, will lead the expansion of the global hairy cell leukemia therapeutics market at a CAGR of over 6% during the forecast period.

Advent of novel therapies

The global hairy cell leukemia therapeutics market has been witnessing some advances in research since the beginning of the 21st century, which have led to the launch of a few novel therapies for the treatment of hairy cell leukemia and other hematologic malignancies. The strong prevalence of various types of blood cancer at the global level has necessitated the need for the development of advanced therapies, such as kinase inhibitors and gene therapies, to treat such conditions. Such advents of novel therapies are likely to offset the challenges posed by the adverse effects of chemotherapy drugs in the future: which will contribute to the growth of the market during the forecast period.

For the detailed list of factors that will drive the global hairy cell leukemia therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global hairy cell leukemia therapeutics market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hairy cell leukemia therapeutics manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.

Also, the hairy cell leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Chemotherapy – Market size and forecast 2018-2023

Targeted therapy – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing research grants for blood cancers

Advent of novel therapies

Special drug designations

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AstraZeneca Plc

F. Hoffmann-La Roche Ltd.

Merck & Co., Inc.

Mylan NV

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Chemotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Chemotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 22: Targeted therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Targeted therapy – Year-over-year growth 2019-2023 (%)

Exhibit 24: Patient assistance programs

Exhibit 25: Market opportunity by product

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: North America – Year-over-year growth 2019-2023 (%)

Exhibit 31: Top 3 countries in North America

Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in Europe

Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Proportion of geriatric population in Asia 2009 and 2018

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Growth in geriatric population 2014-2018 (%)

Exhibit 45: Side effects of chemotherapy drugs used for treatment of hairy cell leukemia

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Drug designations

Exhibit 48: Vendor landscape

Exhibit 49: Landscape disruption

Exhibit 50: Vendors covered

Exhibit 51: Vendor classification

Exhibit 52: Market positioning of vendors

Exhibit 53: AstraZeneca Plc – Vendor overview

Exhibit 54: AstraZeneca Plc – Business segments

Exhibit 55: AstraZeneca Plc – Organizational developments

Exhibit 56: AstraZeneca Plc – Geographic focus

Exhibit 57: AstraZeneca Plc – Key offerings

Exhibit 58: AstraZeneca Plc – Key customers

Exhibit 59: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 60: F. Hoffmann-La Roche Ltd. – Product segments

Exhibit 61: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 62: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 63: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 64: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 65: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 66: Merck & Co. Inc. – Vendor overview

Exhibit 67: Merck & Co. Inc. – Business segments

Exhibit 68: Merck & Co. Inc. – Organizational developments

Exhibit 69: Merck & Co. Inc. – Geographic focus

Exhibit 70: Merck & Co. Inc. – Segment focus

Exhibit 71: Merck & Co. Inc. – Key offerings

Exhibit 72: Merck & Co. Inc. – Key customers

Exhibit 73: Mylan NV – Vendor overview

Exhibit 74: Mylan NV – Product segments

Exhibit 75: Mylan NV – Organizational developments

Exhibit 76: Mylan NV – Geographic focus

Exhibit 77: Mylan NV – Segment focus

Exhibit 78: Mylan NV – Key offerings

Exhibit 79: Mylan NV – Key customers

Exhibit 80: Pfizer Inc. – Vendor overview

Exhibit 81: Pfizer Inc. – Business segments

Exhibit 82: Pfizer Inc. – Organizational developments

Exhibit 83: Pfizer Inc. – Geographic focus

Exhibit 84: Pfizer Inc. – Segment focus

Exhibit 85: Pfizer Inc. – Key offerings

Exhibit 86: Pfizer Inc. – Key customers

Exhibit 87: Validation techniques employed for market sizing

Exhibit 88: Definition of market positioning of vendors



【掲載企業】

AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 有毛細胞白血病治療薬の世界市場:化学療法、標的療法(Global Hairy Cell Leukemia Therapeutics Market 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆